哌拉西林他唑巴坦治疗COPD合并吸入性肺炎疗效和安全性评价.docxVIP

哌拉西林他瞠巴坦治疗COPD合并吸入性肺炎疗效和安全性评价 摘要：目的评价哌拉西林-他呢巴坦治疗COPD合并 吸入性肺炎(AP)的临床疗效和安全性。方法回顾性分析 哌拉西林他p坐巴坦治疗47例COPD合并AP患者的临床疗效、 细菌学评价和安全性分析。结果哌拉西林他13坐巴坦治疗 COPD合并AP患者有效率为78. 7%,痊愈率29. 8%,细菌清除 率为75. 9%,不良反应发生率为4. 3%o结论 哌拉西林-他哇 巴坦治疗COPD合并AP患者疗效好，安全性高。 关键词：哌拉西林-他哇巴坦；COPD；吸入性肺炎 The Clinical Efficacy and Safety Evaluation of Piperaci11in-tazobactam in the Treatment of Patients with COPD Complicated by Aspiration Pneumonia CHEN Li-yan, WU Hua, WANG Lu-lin (Guangzhou Medical University the 1st Affiliated Hospital Department of Respiratory Diseases , Guangzhou Institute of Respiratory Disease, Guangzhou Medical University State Key Laboratory of Respiratory Disease, Guangzhou, Guangdon, 510120, China) Abstract： Objective： To evaluate the efficacy and safety of piperacillin—tazobactam in the treatment of patients with COPD complicated by aspiration pneumonia. Metheds : 47 patients with COPD complicated by aspiration pneumonia who were treated with piperacillin- tazobactam were enrolled in this study by retrospective analysis? The treatment duration was 7-14 days .The clinical efficacy , bacterial eradication rate， and safety were analyzed. ResuIts： The total effective rate of piperacillin- tazobactam was 78. 7% and the curative rate was 29. 8%. The bacterial eradication rate was 75.9% while the rate of adverse effect was 4. 3%. Conclusion： Piperacillin- tazobactam is effective and safe in the treatment of patients with COPD complicated by aspiration pneumonia. Key words : Piperaci11in-tazobactam , COPD , Aspiration Pneumonia 吸入性肺炎(Aspiration Pneumonia, AP)是指口咽 部分泌物或胃内容物被吸入下呼吸道后所导致的肺部炎症 。国外有报道，健康的老年人(年龄＞80岁)100%存在吞 咽功能和咳嗽反射的减退，年龄就是误吸的独立危险因素 。随着我国人口的老龄化，AP的发生率日益增加。COPD 患者多为老年患者，因长期呼吸疲劳合并吞咽功能障碍、呛 咳等误吸高危因素，容易合并出现AP[3-4]O且COPD患者咳 嗽能力减弱，免疫力降低，基础肺功能差，死亡率较高，有 效的感染控制是治疗COPD合并AP患者的重要措施之一。本 研究对47例患者的临床资料进行回顾性分析，探讨哌拉西 林他哩巴坦治疗COPD合并AP患者的临床有效性和安全性。 1资料与方法 1. 1 一般资料 调查对象为2011年9月1日?2012年8 月31日在我院住院，应用哌拉西林他哩巴坦治疗的47例 COPD合并AP患者。年龄47?89岁，平均年龄(70.9±11.8) 岁，男性36 (76.6%)例，女性11 (23.4%)例。全部患者 均存在不同程度吞咽功能障碍导致进食呛咳